For the Season 2 finale, we’re at the 2016 annual meeting of the American Society of Hematology (ASH). You’ll hear from Dr Alexis Thompson, Dr Brian Druker, Dr Bruce Cheson and Dr John Leonard on some of the latest developments in hematology.

ASH16 Sand Sculpture on Curing Sickle Cell Disease

Sickle Cell Disease – Interview with Dr Alexis Thompson

Dr Alexis Thompson at ASH16Alexis A Thompson MD MPH is Professor Pediatrics (Hematology, Oncology and Stem Cell Transplantation) at the Northwestern University Feinberg School of Medicine in Chicago. A Vice President of the American Society of Hematology (ASH), she will become President in 2018.

In this episode we’re targeting ovarian cancer: PARP inhibitors, biomarkers and novel immunotherapy combinations. You’ll hear from  Professor George Coukos, Dr Rebecca Kristeleit and other ovarian cancer experts about some of the data presented at the 2016 Congress of European Society for Medical Oncology (ESMO) in Copenhagen.


Interview with Professor George Coukos, University of Lausanne, Switzerland

Professor George CoukosProfessor George Coukos is Head of the Department of Oncology at the University of Lausanne and Director of the Swiss branch of the Ludwig Institute for Cancer Research.

How do we make CAR T cell therapy more safe and effective? How can we target solid tumors? In this episode we hear from two cell therapy pioneers: Dr Michael Jensen & Dr Michel Sadelain.

Dr Michel Sadelain Biotech Strategy Blog Interview

Interview with Dr Michel Sadelain

Dr Michel Sadelain (pictured) is Director of the Center for Cell Engineering at Memorial Sloan Kettering Cancer Center in New York. He’s spent the last 25 years pioneering new approaches to adoptive cell therapy.

Dr Sadelain and colleagues at Memorial were responsible for the development of what is known as the second generation Chimeric Antigen Receptor (CAR) T cell construct and for identifying CD19 as a target.

This episode comes from ASCO 2016 in Chicago, the annual meeting of the American Society of Clinical Oncology. In it, you’ll hear experts such as Dr Johanna Bendell, Dr Jérôme Galon, and Dr Stephen Liu talk about some of the latest cancer immunotherapy data.


Dr Jérôme Galon ASCO 2016

Dr Jérôme Galon presenting Immunoscore data at ASCO 2016


One of the ASCO presentations featured in this podcast episode was by Dr Jérôme Galon (INSERM), who presented the results of a global clinical trial that validated Immunoscore as a prognostic marker in Stage I/II/III colon cancer (ASCO 2016 abstract #3500).

At the 2016 annual meeting of the American Association for Cancer Research (AACR) one topic that attracted a lot of attention and debate was the use of mouse models to guide cancer immunotherapy drug development strategy.

Dr Bernie Fox AACR 2016 New Orleans

Bernard A. Fox, PhD (pictured above) is Chief, Laboratory of Molecular and Tumor Immunology and holds the Harder Family Chair for Cancer Research at the Earle A. Chiles Research Institute at Providence Cancer Center. He’s also President and CEO of UbiVac.

You can follow him on Twitter at @BernardAFox.